{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:14:03Z","timestamp":1777115643473,"version":"3.51.4"},"reference-count":39,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Cystic fibrosis (CF) is a genetic and multisystemic disease that requires a high therapeutic demand for its control. The aim of this study was to assess therapeutic adherence (TA) to different treatments to study possible clinical consequences and clinical factors influencing adherence. This is an ambispective observational study of 57 patients aged over 18 years with a diagnosis of CF. The assessment of TA was calculated using the Medication Possession Ratio (MPR) index. These data were related to exacerbations and the rate of decline in FEV1 percentage. Compliance was good for all CFTR modulators, azithromycin, aztreonam, and tobramycin in solution for inhalation. The patients with the best compliance were older; they had exacerbations and the greatest deterioration in lung function during this period. The three variables with the highest importance for the compliance of the generated Random Forest (RF) models were age, FEV1%, and use of Ivacaftor\/Tezacaftor. This is one of the few studies to assess adherence to CFTR modulators and symptomatic treatment longitudinally. CF patient therapy is expensive, and the assessment of variables with the highest importance for a high MPR, helped by new Machine learning tools, can contribute to defining new efficient TA strategies with higher benefits.<\/jats:p>","DOI":"10.3390\/antibiotics11111637","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T03:12:20Z","timestamp":1668654740000},"page":"1637","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Longitudinal Study of Therapeutic Adherence in a Cystic Fibrosis Unit: Identifying Potential Factors Associated with Medication Possession Ratio"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-0848","authenticated-orcid":false,"given":"Rosa M\u00aa","family":"Gir\u00f3n","sequence":"first","affiliation":[{"name":"Servicio de Neumolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria de La Princesa, Diego de Le\u00f3n n\u00ba62, 28006 Madrid, Spain"},{"name":"Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, 28049 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0284-6643","authenticated-orcid":false,"given":"Adri\u00e1n","family":"Pel\u00e1ez","sequence":"additional","affiliation":[{"name":"Servicio de Neumolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria de La Princesa, Diego de Le\u00f3n n\u00ba62, 28006 Madrid, Spain"},{"name":"Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, 28049 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria, Hospital Universitario de La Princesa, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2968-1271","authenticated-orcid":false,"given":"Elisa","family":"Mart\u00ednez-Besteiro","sequence":"additional","affiliation":[{"name":"Servicio de Neumolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria de La Princesa, Diego de Le\u00f3n n\u00ba62, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2484-5908","authenticated-orcid":false,"given":"Rosa Mar","family":"G\u00f3mez-Punter","sequence":"additional","affiliation":[{"name":"Servicio de Neumolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria de La Princesa, Diego de Le\u00f3n n\u00ba62, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7379-8848","authenticated-orcid":false,"given":"Adri\u00e1n","family":"Mart\u00ednez-Vergara","sequence":"additional","affiliation":[{"name":"Servicio de Neumolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria de La Princesa, Diego de Le\u00f3n n\u00ba62, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Ancochea","sequence":"additional","affiliation":[{"name":"Servicio de Neumolog\u00eda, Instituto de Investigaci\u00f3n Sanitaria de La Princesa, Diego de Le\u00f3n n\u00ba62, 28006 Madrid, Spain"},{"name":"Facultad de Medicina, Universidad Aut\u00f3noma de Madrid, 28049 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4937-4292","authenticated-orcid":false,"given":"Alberto","family":"Morell","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria, Hospital Universitario de La Princesa, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: Challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/17476348.2017.1280399","article-title":"Adherence to therapies in cystic fibrosis: A targeted literature review","volume":"11","author":"Narayanan","year":"2016","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Moreno, R.G., Garc\u00eda-Clemente, M., Diab-C\u00e1ceres, L., Mart\u00ednez-Vergara, A., Mart\u00ednez-Garc\u00eda, M., and G\u00f3mez-Punter, R. (2021). Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics, 10.","DOI":"10.3390\/antibiotics10050486"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Munck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): An open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Carnovale, V., Iacotucci, P., Terlizzi, V., Colangelo, C., Ferrillo, L., Pepe, A., Francalanci, M., Taccetti, G., Buonaurio, S., and Celardo, A. (2022). Elexacaftor\/Tezacaftor\/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041021"},{"key":"ref_9","unstructured":"World Health Organization (2021, June 08). Adherence to Long-Term Therapies: Evidence for Action. Available online: https:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_report\/en\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1378\/chest.13-1926","article-title":"Pulmonary Medication Adherence and Health-care Use in Cystic Fibrosis","volume":"146","author":"Quittner","year":"2014","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/MCP.0b013e3283659f45","article-title":"The impact of medication adherence on lung health outcomes in cystic fibrosis","volume":"19","author":"Eakin","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/thx.51.1.29","article-title":"Compliance with treatment in adult patients with cystic fibrosis","volume":"51","author":"Conway","year":"1996","journal-title":"Thorax"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/thx.49.2.115","article-title":"Treatment compliance in adults with cystic fibrosis","volume":"49","author":"Abbott","year":"1994","journal-title":"Thorax"},{"key":"ref_14","first-page":"163","article-title":"M\u00e9todos para medir la adhesi\u00f3n terape\u00fatica","volume":"59","year":"2018","journal-title":"Ars Pham."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jcf.2006.03.002","article-title":"A multi-method assessment of treatment adherence for chil-dren with cystic fibrosis","volume":"5","author":"Modi","year":"2006","journal-title":"J. Cyst. Fibros."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MCP.0000000000000244","article-title":"The psychological burden of cystic fibrosis","volume":"22","author":"Quittner","year":"2016","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Liu, M., Xu, X., Tao, Y., and Wang, X. (2017, January 21\u201324). An improved random forest method based on RELIEFF for medical diagnosis. Proceedings of the 2017 IEEE International Conference on Computational Science and Engineering (CSE) and IEEE International Confer-ence on Embedded and Ubiquitous Computing (EUC), Guangzhou, China.","DOI":"10.1109\/CSE-EUC.2017.19"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Strobl, C., Boulesteix, A.L., Zeileis, A., and Hothorn, T. (2007). Bias in random forest variable importance measures: Illustrations, sources and a solution. BMC Bioinformat., 8.","DOI":"10.1186\/1471-2105-8-25"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105534","DOI":"10.1016\/j.fishres.2020.105534","article-title":"The predictive performances of random forest models with limited sample size and different species traits","volume":"227","author":"Luan","year":"2020","journal-title":"Fish. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1198\/tast.2009.08199","article-title":"Variable Importance Assessment in Regression: Linear Regression versus Random Forest","volume":"63","year":"2009","journal-title":"Am. Stat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102744","DOI":"10.1016\/j.healthplace.2022.102744","article-title":"Ranking the importance of demographic, socioeconomic, and underlying health factors on US COVID-19 deaths: A geographical random forest approach","volume":"74","author":"Grekousis","year":"2022","journal-title":"Health Place"},{"key":"ref_22","unstructured":"(2020, March 09). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available online: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4014\/jmb.2003.03011","article-title":"Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)","volume":"30","author":"Ahn","year":"2020","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/21556660.2021.1912352","article-title":"Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: Analysis of a national specialty pharmacy database","volume":"10","author":"Mehta","year":"2021","journal-title":"J. Drug Assess."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/bib\/bbq011","article-title":"Letter to the Editor: Stability of Random Forest importance measures","volume":"12","author":"Calle","year":"2010","journal-title":"Briefings Bioinform."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/ppul.25834","article-title":"Adherence to inhaled therapies over 4 years in people with cystic fibrosis","volume":"57","author":"Manika","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/medu.13204","article-title":"A new paradigm for clinical communication: Critical review of literature in cancer care","volume":"51","author":"Salmon","year":"2016","journal-title":"Med. Educ."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2011.03.005","article-title":"Longitudinal association between medication adherence and lung health in people with cystic fibrosis","volume":"10","author":"Eakin","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jcf.2012.12.012","article-title":"Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time","volume":"12","author":"Ball","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"675766","DOI":"10.3389\/fpubh.2021.675766","article-title":"Identification of variable importance for predictions of mortality from COVID-19 using AI models for Ontario, Canada","volume":"9","author":"Snider","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Soogun, A.O., Kharsany, A., Zewotir, T., North, D., and Ogunsakin, R.E. (2022). Identifying Potential Factors Associated with High HIV viral load in KwaZulu-Natal, South Africa using Multiple Correspondence Analysis and Random Forest Analysis. BMC Med. Res. Methodol., 22.","DOI":"10.1186\/s12874-022-01625-6"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13567-015-0219-7","article-title":"What variables are important in predicting bovine viral diarrhea virus? A random forest approach","volume":"46","author":"Machado","year":"2015","journal-title":"Vet. Res."},{"key":"ref_33","first-page":"270","article-title":"Using A Work System Framework to Investigate Pharmacists\u2019 Roles in Cystic Fibrosis Management","volume":"27","author":"Abraham","year":"2022","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ppul.23743","article-title":"Impact of pharmacy services on cystic fibrosis medication adherence","volume":"52","author":"Zobell","year":"2017","journal-title":"Pediatr. Pulmonol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.japh.2018.01.006","article-title":"The pharmacist\u2019s role in supporting people living with cystic fibrosis","volume":"58","author":"Abraham","year":"2018","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_36","first-page":"283","article-title":"Cystic fibrosis outpatient treatment andmedical costs: A retrospective an\u00e1lisis","volume":"30","author":"Orzaiz","year":"2020","journal-title":"Ofil\u00b7Ilaphar"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Davis, S., Rosenfeld, M., and Chmiel, J. (2020). Understanding Treatment Adherence in Cystic Fibrosis: Challenges and Opportunities. Cystic Fibrosis: A Multi-Organ System Approach: A Multi-Organ System Approach, Humana.","DOI":"10.1007\/978-3-030-42382-7"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1513\/AnnalsATS.202010-1336SD","article-title":"Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design","volume":"18","author":"Nichols","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_39","unstructured":"(2022, September 27). CF STORM; A Trial to Assess Change in Respiratory Function for People with Cystic Fibrosis on Triple Combination Therapy (Kaftrio\u2122) after Rationalisation of Nebulised Mucoactive Therapies. Available online: https:\/\/www.cfstorm.org.uk."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/11\/1637\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:19:28Z","timestamp":1760145568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/11\/1637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["antibiotics11111637"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11111637","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]}}}